These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29409309)

  • 1. Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.
    Lee HW; Oh SR; Kim DY; Jeong Y; Kim S; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
    Gut Liver; 2018 May; 12(3):324-330. PubMed ID: 29409309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
    Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
    Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
    McPhee F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Yu ML; Ahn SH; Ishikawa H; Bhore R; Zhou N; Hernandez D; Mendez P; Kumada H
    Adv Ther; 2015 Jul; 32(7):637-49. PubMed ID: 26155891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
    Lee BS; Song MJ; Kwon JH; Lee TH; Jang JW; Kim SH; Lee SH; Kim HS; Kim JH; Kim SB; Ko SY; Song DS
    Gut Liver; 2019 Mar; 13(2):191-196. PubMed ID: 30400729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.
    Wang HL; Lu X; Yang X; Xu N
    J Gastroenterol Hepatol; 2017 Jan; 32(1):45-52. PubMed ID: 27597318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
    Lu Y; Jin X; Duan CA; Chang F
    PLoS One; 2018; 13(4):e0195117. PubMed ID: 29634736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
    Yu ML; Hung CH; Huang YH; Peng CY; Lin CY; Cheng PN; Chien RN; Hsu SJ; Liu CH; Huang CF; Su CW; Huang JF; Liu CJ; Kao JH; Chuang WL; Chen PJ; Chen DS
    J Formos Med Assoc; 2019 Feb; 118(2):556-564. PubMed ID: 30527566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
    Suda G; Furusyo N; Toyoda H; Kawakami Y; Ikeda H; Suzuki M; Arataki K; Mori N; Tsuji K; Katamura Y; Takaguchi K; Ishikawa T; Tsuji K; Shimada N; Hiraoka A; Yamsaki S; Nakai M; Sho T; Morikawa K; Ogawa K; Kudo M; Nagasaka A; Furuya K; Yamamoto Y; Kato K; Ueno Y; Iio E; Tanaka Y; Kurosaki M; Kumada T; Chayama K; Sakamoto N
    J Gastroenterol; 2018 Jan; 53(1):119-128. PubMed ID: 28560477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
    Iio E; Shimada N; Abe H; Atsukawa M; Yoshizawa K; Takaguchi K; Eguchi Y; Nomura H; Kuramitsu T; Kang JH; Matsui T; Hirashima N; Tsubota A; Kusakabe A; Hasegawa I; Miyaki T; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
    J Gastroenterol; 2017 Jan; 52(1):94-103. PubMed ID: 27236547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
    Nam HC; Lee HL; Yang H; Song MJ
    Clin Mol Hepatol; 2016 Jun; 22(2):259-66. PubMed ID: 27377910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
    Sezaki H; Suzuki F; Hosaka T; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Liver Int; 2017 Sep; 37(9):1325-1333. PubMed ID: 28178397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
    Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    Uchida Y; Naiki K; Kouyama JI; Sugawara K; Nakao M; Motoya D; Inao M; Nakayama N; Imai Y; Tomiya T; Mochida S
    PLoS One; 2018; 13(10):e0205600. PubMed ID: 30308053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
    Morio K; Imamura M; Kawakami Y; Morio R; Kobayashi T; Yokoyama S; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Makokha GN; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
    J Gastroenterol Hepatol; 2017 Mar; 32(3):645-650. PubMed ID: 27513614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
    Suzuki F; Hatanaka N; Bando E; Nakamura K; Komoto A
    Hepatol Int; 2018 May; 12(3):244-253. PubMed ID: 29900486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
    Shin SK; Lee JW; Ra H; Kwon OS; Shin JB; Jin YJ; Lee S; Han KJ; Kim YN; Kim TH; Kim YS; Kim JH
    J Korean Med Sci; 2019 Oct; 34(41):e264. PubMed ID: 31650719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
    Toyota J; Karino Y; Suzuki F; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; Hu W; McPhee F; Linaberry M; Yin PD; Swenson ES; Kumada H
    J Gastroenterol; 2017 Mar; 52(3):385-395. PubMed ID: 27502287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
    Kao JH; Jensen DM; Manns MP; Jacobson I; Kumada H; Toyota J; Heo J; Yoffe B; Sievert W; Bessone F; Peng CY; Roberts SK; Lee YJ; Bhore R; Mendez P; Hughes E; Noviello S
    Liver Int; 2016 Jul; 36(7):954-62. PubMed ID: 26683763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
    Oh JY; Kim BS; Lee CH; Song JE; Lee HJ; Park JG; Hwang JS; Chung WJ; Jang BK; Kweon YO; Tak WY; Park SY; Jang SY; Suh JI; Kwak SG
    Korean J Intern Med; 2019 Jul; 34(4):794-801. PubMed ID: 29792020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
    Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
    Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.